Foghorn Therapeutics Inc. has announced the appointment of Neil Gallagher, M.D., Ph.D., and Stuart Duty to its Board of Directors. The company, focusing on developing new medicines to treat serious diseases by correcting abnormal gene expression, aims to leverage the extensive industry experience of Gallagher and Duty to advance its clinical and preclinical pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.